For personal use only
Living Cell Technologies Limited
ACN: 104 028 042
ASX: LCT
OTCQB: LVCLY
ASX ANNOUNCEMENT
Change of Directors' Interest Notice
Sydney, Australia & Auckland, New Zealand - 28 July 2022 - Living Cell Technologies (ASX: LCT) wishes to advise pursuant to the Renounceable Rights Offer first announced to the market on 15 November 2021, that directors Professor Bernie Tuch and Dr Andrew Kelly participated in the retail component of the offer, but due to an administrative oversight, the attached updated Appendix 3Ys were not lodged within the required time frame.
The Company has reviewed its processes in this regard in order to prevent a reoccurrence.
This announcement is authorised for release by Mark Licciardo, Company Secretary.
- Ends - | |||
For further information: www.lctglobal.com | |||
At the Company: | For media queries: | ||
Bernie Tuch | Anthony Fensom | ||
Chief Executive | Republic PR | ||
Mobile: +61 411 461 604 | Mobile: +61 407 112 623 | ||
bernietuch@lctglobal.com | anthony@republicpr.com.au | ||
For personal use only
About NTCELL
NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.
About Living Cell Technologies
Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.
LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.
For more information, visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.
Forward-looking statements
This document may contain certain forward-looking statements, relating to LCT's business, which canbe identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be,""on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCTis providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developmentsor otherwise.
Appendix 3Y Change of Director's Interest Notice
Appendix 3Y
Rule 3.19A.2
For personal use only
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Living Cell Technologies Limited
ABN | 14 104 028 042 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | Bernard Edward Tuch |
Date of last notice | 13 December 2018 |
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Indirect |
Nature of indirect interest | Director |
(including registered holder) | |
Note: Provide details of the circumstances giving rise to the relevant | |
interest. | |
Date of change | 30 December 2021 |
No. of securities held prior to change | 36,800 fully paid ordinary shares held in |
the name of DTU Pty Limited ATF The | |
Beryl Super Fund | |
600,000 unlisted options | |
held in the name of DTU Pty Limited ATF | |
The Peckham Trust | |
Class | • ordinary shares |
• listed options (exercisable at $0.015 | |
expiring on 19 April 2024) | |
Number acquired | • 24,535 ordinary shares |
• 8,178 listed options | |
Number disposed | nil |
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Value/Consideration | • $0.008 per ordinary share |
Note: If consideration is non-cash, provide details and estimated | • Listed options were attached to the |
valuation | |
rights shares at no cost | |
No. of securities held after change | 61,335 fully paid ordinary shares |
held in the name of DTU Pty Limited ATF | |
The Beryl Super Fund | |
8,178 fully listed options | |
held in the name of DTU Pty Limited ATF | |
The Beryl Super Fund | |
600,000 unlisted options | |
held in the name of DTU Pty Limited ATF | |
The Peckham Trust | |
Nature of change | Issue of securities as per the renounceable |
Example: on-market trade, off-market trade, exercise of options, | rights offer announced on 15 November |
issue of securities under dividend reinvestment plan, participation in | 2021 |
buy-back | |
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | N/A |
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed period
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 | 01/01/2011 |
For personal use only
Appendix 3Y
Change of Director's Interest Notice
Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this provided?
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Living Cell Technologies Limited published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 00:47:03 UTC.